TIDMFUM
RNS Number : 5207Q
Futura Medical PLC
28 June 2022
28 June 2022
Futura Medical plc
("Futura" or the "Company")
Futura Medical Announces Annual General Meeting Results
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, today announces that
at its Annual General Meeting, held today at 10:00am BST, the
shareholders duly passed all resolutions.
The total number of votes received on each resolution were as
follows:
Voting For Voting Against
---------------------------------- -------------------------------------
Number % Number % Total % ISC Votes
of votes(i) of votes Votes withheld(ii)
------------ -------------------- ------------- ------- ---------- ------ ------------ ------- --------------
To accept
the Annual
Resolution Report and
1 accounts 132,535,568 95.80% 5,769,918 4.20% 138,305,486 48.14% 70,831
-------------------- ------------- ------- ---------- ------ ------------ ------- --------------
To appoint
Resolution Jeff Needham
2 as a Director 138,246,246 99.98% 27,676 0.02% 138,273,922 48.13% 102,395
-------------------- ------------- ------- ---------- ------ ------------ ------- --------------
To appoint
Resolution Andrew Unitt
3 as a Director 138,250,441 99.98% 23,481 0.02% 138,273,922 48.13% 102,395
-------------------- ------------- ------- ---------- ------ ------------ ------- --------------
To re-elect
Resolution Ken James
4 as a Director 138,243,746 99.98% 30,676 0.02% 138,274,422 48.13% 101,895
-------------------- ------------- ------- ---------- ------ ------------ ------- --------------
To re-appoint
Grant Thornton
Resolution UK LLP as
5 Auditor 138,244,578 99.96% 49,908 0.04% 138,294,486 48.14% 81,831
-------------------- ------------- ------- ---------- ------ ------------ ------- --------------
To authorise
the Directors
to determine
the remuneration
Resolution of Grant Thornton
6 UK LLP 138,276,015 99.97% 40,471 0.03% 138,316,486 48.14% 59,831
-------------------- ------------- ------- ---------- ------ ------------ ------- --------------
To authorise
the directors
of the Company
to issue and
allot relevant
securities
(up to 1/3
of the existing
issued share
capital) pursuant
to section
551 of the
Resolution Companies
7 Act 2006 138,239,449 99.95% 65,970 0.05% 138,305,419 48.14% 70,898
-------------------- ------------- ------- ---------- ------ ------------ ------- --------------
A Special
Resolution
empowering
the Directors
to disapply
the pre-emption
provision
of section
561 of the
Act in connection
with an offer
of equity
securities
by way of
a Rights Issue
or up to an
aggregate
Resolution nominal value
8 (iii) of GBP28,729.00 138,150,793 99.90% 135,129 0.10% 138,285,922 48.13% 90,395
-------------------- ------------- ------- ---------- ------ ------------ ------- --------------
A Special
Resolution
empowering
the Directors
to disapply
the pre-emption
provision
of section
561 of the
Act in connection
with an offer
of equity
securities
to fund an
acquisition
Resolution or a capital
9 transaction 138,170,921 99.92% 111,934 0.08% 138,282,855 48.13% 93,462
-------------------- ------------- ------- ---------- ------ ------------ ------- --------------
Where shareholders appointed the Chairman as their proxy with
discretion as to voting, their votes were cast in favour of the
resolution
A vote withheld is not a vote in law and is not counted towards
the votes cast "For" or "Against" a resolution
Special Resolution (75% majority required)
The total voting rights of the Company as at 10:00 am on 24 June
2022 (the time by which shareholders wanting to vote at the AGM
were required to be entered on the register) was 287,296,527
ordinary shares of 0.2p each. The Company does not hold any shares
in treasury
-ENDS-
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction ("ED") through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application. MED3000 is CE marked in Europe
and the UK as a clinically proven topical treatment for adult men
with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGFLFESRFITFIF
(END) Dow Jones Newswires
June 28, 2022 10:58 ET (14:58 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2024 to May 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From May 2023 to May 2024